| Phase 19 trials |
|
Phase 1
|
NCT07677358 |
Jul 2026 → Aug 2027 expected |
liver disorder |
Pfizer |
Not yet recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT07215078 |
Oct 2025 → Jun 2026 overdue |
— |
Pfizer |
Recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT07160738 |
Sep → Nov 2025 |
— |
Pfizer |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT07130097 |
Aug → Oct 2025 |
— |
Pfizer |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT06897683 |
Mar → May 2025 |
— |
Pfizer |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT06267963 |
Jan → Apr 2024 |
— |
Pfizer |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT05923411 |
Jul 2023 → Jun 2024 |
— |
Pfizer |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT05508906 |
Aug 2022 → Dec 2027 expected |
Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer, female breast carcinoma, metastatic malignant neoplasm |
Olema Pharmaceuticals, Inc. |
Recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT05216432 |
Dec 2021 → Apr 2027 expected |
Her2-receptor negative breast cancer, PIK3CA-related overgrowth spectrum |
Relay Therapeutics, Inc. |
Recruiting
|
No outcome recorded
|
| Phase 1/23 trials |
|
Phase 1/2
|
NCT06206837 |
Feb 2024 → Sep 2025 overdue |
breast cancer |
Pfizer |
Active not recruiting
|
No outcome recorded
|
|
Phase 1/2
|
NCT05262400 |
Mar 2022 → Aug 2026 overdue |
breast cancer |
Pfizer |
Active not recruiting
|
No outcome recorded
|
|
Phase 1/2
|
NCT03424005 |
Mar 2018 → Sep 2030 expected |
breast cancer |
Hoffmann-La Roche |
Recruiting
|
No outcome recorded
|
| Phase 25 trials |
|
Phase 2
|
NCT07427394 |
May 2026 → Dec 2027 expected |
female breast carcinoma |
AstraZeneca |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06465368 |
Jul 2024 → Jul 2025 |
breast cancer |
Pfizer |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT06105632 |
Jan 2024 → Jan 2026 overdue |
breast cancer |
Pfizer |
Active not recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT04606446 |
Nov 2020 → Jul 2029 expected |
breast cancer, castration-resistant prostate carcinoma, non-small cell lung carcinoma |
Pfizer |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT04557449 |
Sep 2020 → Sep 2026 expected |
breast neoplasm, liposarcoma, lung adenocarcinoma, prostate cancer |
Pfizer |
Active not recruiting
|
No outcome recorded
|
| Phase 31 trial |
|
Phase 3
|
NCT06760637 |
Jan 2025 → Jan 2029 expected |
breast cancer |
Pfizer |
Active not recruiting
|
No outcome recorded
|